Aridis Pharmaceuticals is a biopharmaceutical company that develops targeted immunotherapy to treat life-threatening infections using fully human monoclonal antibodies. Its leading product candidate is AR-301, which is in Phase III trials to treat lung infections from S. aureus alphatoxin. The company is also developing other fully human monoclonal antibodies to treat infections caused by different types of bacteria and viruses.